Literature DB >> 33538585

Synthetic Biology and Computer-Based Frameworks for Antimicrobial Peptide Discovery.

Marcelo D T Torres1,2,3, Jicong Cao4, Octavio L Franco5,6, Timothy K Lu4, Cesar de la Fuente-Nunez1,2,3.   

Abstract

Antibiotic resistance is one of the greatest challenges of our time. This global health problem originated from a paucity of truly effective antibiotic classes and an increased incidence of multi-drug-resistant bacterial isolates in hospitals worldwide. Indeed, it has been recently estimated that 10 million people will die annually from drug-resistant infections by the year 2050. Therefore, the need to develop out-of-the-box strategies to combat antibiotic resistance is urgent. The biological world has provided natural templates, called antimicrobial peptides (AMPs), which exhibit multiple intrinsic medical properties including the targeting of bacteria. AMPs can be used as scaffolds and, via engineering, can be reconfigured for optimized potency and targetability toward drug-resistant pathogens. Here, we review the recent development of tools for the discovery, design, and production of AMPs and propose that the future of peptide drug discovery will involve the convergence of computational and synthetic biology principles.

Entities:  

Keywords:  antimicrobial peptides; computational biology; molecular design frameworks; peptide chemistry; peptide design; peptide discovery; rational design; synthetic biology

Mesh:

Substances:

Year:  2021        PMID: 33538585      PMCID: PMC8734659          DOI: 10.1021/acsnano.0c09509

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   15.881


  206 in total

Review 1.  Host-defense antimicrobial peptides: importance of structure for activity.

Authors:  N Sitaram; R Nagaraj
Journal:  Curr Pharm Des       Date:  2002       Impact factor: 3.116

Review 2.  The cyclization of peptides and depsipeptides.

Authors:  John S Davies
Journal:  J Pept Sci       Date:  2003-08       Impact factor: 1.905

Review 3.  The heterologous expression strategies of antimicrobial peptides in microbial systems.

Authors:  Ting Deng; Haoran Ge; Huahua He; Yao Liu; Chao Zhai; Liang Feng; Li Yi
Journal:  Protein Expr Purif       Date:  2017-08-12       Impact factor: 1.650

4.  Semaphorin 3A lytic hybrid peptide binding to neuropilin-1 as a novel anti-cancer agent in pancreatic cancer.

Authors:  Hanae Ueyama; Tomohisa Horibe; Oumi Nakajima; Koji Ohara; Masayuki Kohno; Koji Kawakami
Journal:  Biochem Biophys Res Commun       Date:  2011-09-14       Impact factor: 3.575

Review 5.  The coming of age of de novo protein design.

Authors:  Po-Ssu Huang; Scott E Boyken; David Baker
Journal:  Nature       Date:  2016-09-15       Impact factor: 49.962

6.  Anti-adhesive antimicrobial peptide coating prevents catheter associated infection in a mouse urinary infection model.

Authors:  Kai Yu; Joey C Y Lo; Mei Yan; Xiaoqiang Yang; Donald E Brooks; Robert E W Hancock; Dirk Lange; Jayachandran N Kizhakkedathu
Journal:  Biomaterials       Date:  2016-11-24       Impact factor: 12.479

7.  Free energy determinants of secondary structure formation: I. alpha-Helices.

Authors:  A S Yang; B Honig
Journal:  J Mol Biol       Date:  1995-09-22       Impact factor: 5.469

8.  Prediction of antimicrobial peptides based on the adaptive neuro-fuzzy inference system application.

Authors:  Fabiano C Fernandes; Daniel J Rigden; Octavio L Franco
Journal:  Biopolymers       Date:  2012       Impact factor: 2.505

9.  Cationicity-enhanced analogues of the antimicrobial peptides, AcrAP1 and AcrAP2, from the venom of the scorpion, Androctonus crassicauda, display potent growth modulation effects on human cancer cell lines.

Authors:  Qiang Du; Xiaojuan Hou; Lilin Ge; Renjie Li; Mei Zhou; Hui Wang; Lei Wang; Minjie Wei; Tianbao Chen; Chris Shaw
Journal:  Int J Biol Sci       Date:  2014-09-21       Impact factor: 6.580

10.  Large-scale mapping of bioactive peptides in structural and sequence space.

Authors:  Agustina E Nardo; M Cristina Añón; Gustavo Parisi
Journal:  PLoS One       Date:  2018-01-19       Impact factor: 3.240

View more
  7 in total

1.  Mining for encrypted peptide antibiotics in the human proteome.

Authors:  Marcelo D T Torres; Marcelo C R Melo; Orlando Crescenzi; Eugenio Notomista; Cesar de la Fuente-Nunez
Journal:  Nat Biomed Eng       Date:  2021-11-04       Impact factor: 25.671

2.  Editorial: Antimicrobial Peptides: Molecular Design, Structure-Function Relationship, and Biosynthesis Optimization.

Authors:  Ya Hao; Jianhua Wang; Cesar de la Fuente-Nunez; Octavio Luiz Franco
Journal:  Front Microbiol       Date:  2022-04-11       Impact factor: 5.640

3.  Designing Self-Assembling Chimeric Peptide Nanoparticles with High Stability for Combating Piglet Bacterial Infections.

Authors:  Peng Tan; Qi Tang; Shenrui Xu; Yucheng Zhang; Huiyang Fu; Xi Ma
Journal:  Adv Sci (Weinh)       Date:  2022-03-13       Impact factor: 17.521

4.  Autonomous Treatment of Bacterial Infections in Vivo Using Antimicrobial Micro- and Nanomotors.

Authors:  Xavier Arqué; Marcelo D T Torres; Tania Patiño; Andreia Boaro; Samuel Sánchez; Cesar de la Fuente-Nunez
Journal:  ACS Nano       Date:  2022-04-29       Impact factor: 18.027

Review 5.  Present and Future Perspectives on Therapeutic Options for Carbapenemase-Producing Enterobacterales Infections.

Authors:  Corneliu Ovidiu Vrancianu; Elena Georgiana Dobre; Irina Gheorghe; Ilda Barbu; Roxana Elena Cristian; Mariana Carmen Chifiriuc
Journal:  Microorganisms       Date:  2021-03-31

Review 6.  Traditional and Computational Screening of Non-Toxic Peptides and Approaches to Improving Selectivity.

Authors:  Alberto A Robles-Loaiza; Edgar A Pinos-Tamayo; Bruno Mendes; Josselyn A Ortega-Pila; Carolina Proaño-Bolaños; Fabien Plisson; Cátia Teixeira; Paula Gomes; José R Almeida
Journal:  Pharmaceuticals (Basel)       Date:  2022-03-08

Review 7.  Probiotic engineering strategies for the heterologous production of antimicrobial peptides.

Authors:  Adriana Mejía-Pitta; Esther Broset; Cesar de la Fuente-Nunez
Journal:  Adv Drug Deliv Rev       Date:  2021-07-14       Impact factor: 17.873

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.